The derivatives showing potent anti‐BMI1/MCL1 effect, such as compounds #43–45, were selected for further in vivo anti‐tumour test (Figure S6G), in which compound #44 (named as BI‐44 in this study) showed significant anti‐tumour growth effect. This evidence concerns the gene MCL1 and neoplasm.